Takeda (NYSE: TAK) insider plans Rule 144 sale of 29,619 ADSs on NYSE

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited shareholder plans to sell American Depositary Shares under Rule 144. The notice covers the proposed sale of 29,619 ADSs through Interactive Brokers LLC on the NYSE, with an aggregate market value of $421,182.18. The filing states that 123,490,548 ADSs were outstanding at the time of the notice. The ADSs to be sold were acquired as vested restricted stock unit awards from Takeda on three dates, with 20,046 ADSs acquired on July 1, 2023, 13,592 ADSs on July 1, 2022, and 5,858 ADSs on July 1, 2021, each described as compensation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	29619	421182.18	123490548	12/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2023	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			20046	07/01/2023	Compensation
ADSs	07/01/2022	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			13592	07/01/2022	Compensation
ADSs	07/01/2021	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			5858	07/01/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for TAK disclose?

The Form 144 for Takeda Pharmaceutical Company Limited (TAK) discloses a shareholder’s intention to sell 29,619 American Depositary Shares (ADSs) under Rule 144 on the NYSE.

How many Takeda (TAK) ADSs are planned to be sold and on which exchange?

The notice covers the proposed sale of 29,619 Takeda ADSs, to be sold on the NYSE through Interactive Brokers LLC.

What is the aggregate market value of the Takeda ADSs to be sold?

The planned sale of 29,619 ADSs has an aggregate market value of $421,182.18 as stated in the filing.

How many Takeda ADSs were outstanding according to this Form 144?

The filing reports that 123,490,548 Takeda ADSs were outstanding at the time of the notice.

How were the Takeda ADSs being sold under this Form 144 originally acquired?

The ADSs were acquired as vested restricted stock unit (RSU) awards from Takeda, with 20,046 ADSs on July 1, 2023, 13,592 ADSs on July 1, 2022, and 5,858 ADSs on July 1, 2021, each described as compensation.

What approximate sale date is indicated in the Takeda Form 144?

The shareholder indicates an approximate sale date of December 9, 2025 for the ADSs listed in the notice.